The ACCC has announced that it will not oppose the merger of generics companies Arrow and Apotex. Once combined, the two companies would supply around half the market for generic prescription pharmaceuticals to pharmacies in Australia.
The announcement that Strides Pharma Science Ltd and Apotex Inc planned to merge Arrow Pharmaceuticals and Apotex Australia was made on May 18, 2018.
The ACCC says that after market inquiries and analysis of documents and data, the ACCC considers that the merger will not substantially reduce competition in any market.
Full Content: AJP
Featured News
FTC Lawyers Wrap Up Arguments to Block Kroger-Albertsons Merger
Sep 17, 2024 by
CPI
Financial Regulator to Monitor CNMC’s Ruling on BBVA-Sabadell Acquisition
Sep 17, 2024 by
CPI
Green Day Ticket Prices Spark Controversy Amid Dynamic Pricing Concerns
Sep 17, 2024 by
CPI
Michael Kors Points to TikTok and Taylor Swift in Defense of Luxury Handbag Market in FTC Case
Sep 17, 2024 by
CPI
Irish Watchdog Probes Google’s AI Data Practices
Sep 17, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
Francisco Javier Núñez Melgoza
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
Julio Garcia
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
Alejandra Palacios Prieto
The Cost of Making COFECE Disappear
Sep 3, 2024 by
Mateo Fernández